The second analysis, encompassing three RCTs with 1,735 patients with MGMT-nonmethylated GBM (866 in the experimental group and 869 in the control group), reported an HR of 0.604 (95% CI 0.511 to 0.715; evidence level: high; Class IV) (Figure 4). The gene discussed is MGMT; the disease is glioblastoma.